Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

13.5%

5 terminated/withdrawn out of 37 trials

Success Rate

78.3%

-8.2% vs industry average

Late-Stage Pipeline

3 trials in Phase 3/4

Results Transparency

28%

5 of 18 completed trials have results

Key Signals

7 recruiting5 with results

Enrollment Performance

Analytics

Phase 1

16(66.7%)

Phase 2

5(20.8%)

Phase 4

2(8.3%)

Phase 3

1(4.2%)

24Total

Phase 1(16)

Phase 2(5)

Phase 4(2)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (37)

Showing 20 of 37 trials

NCT03580655Phase 2Completed

(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis

Role: lead

NCT07264959Recruiting

An Observational Study in Participants With Indolent Systemic Mastocytosis (ISM)

Role: lead

NCT07388511Phase 1Completed

A Study of Elenestinib in Healthy Adult Female Participants

Role: lead

NCT04910685Phase 2Recruiting

(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis

Role: lead

NCT07255638Recruiting

A Non-Interventional Study in Participants With Indolent Systemic Mastocytosis (ISM) in Germany

Role: lead

NCT07143669Recruiting

Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations

Role: lead

NCT06327685Phase 1Recruiting

Avapritinib With Decitabine in Patients With SM-AHN

Role: collaborator

NCT06931405Phase 2Recruiting

Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)

Role: lead

NCT06922448Phase 2Completed

Study of BLU-808 in Allergic Rhinoconjunctivitis

Role: lead

NCT06748001Phase 4Recruiting

Avapritinib Rollover Study

Role: lead

NCT04773782Phase 1Completed

A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling

Role: lead

NCT05252416Phase 1Terminated

(VELA) Study of BLU-222 in Advanced Solid Tumors

Role: lead

NCT03731260Phase 2Active Not Recruiting

(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis

Role: lead

NCT06948032Phase 1Completed

Study of BLU-808 in Healthy Adult Participants

Role: lead

NCT05609942Phase 1Terminated

Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic Malignancies

Role: lead

NCT04862780Phase 1Terminated

(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC

Role: lead

NCT05241873Phase 1Terminated

(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations